Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

Your search for ‘Hyman, Phelps, & McNamara’ returned 249 results

Use advanced search filters to refine your search

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    AstraZeneca's Challenge To Price Negotiation Fails In Federal District Court

    Last Friday, the Delaware District Court rejected AstraZeneca's lawsuit against the Medicare Drug Price Negotiation Program enacted under the Inflation Reduction Act (IRA) and CMS's guidance implementing it.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
  • Article

    FDA Knows Its Own Strength—And It Includes Concentration

    While the Biologics Price Competition and Innovation Act ("BPCIA") is inherently distinct from the Hatch-Waxman Act.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
Article

Surely You Must Be Kidding, PTO?!? "No, And Don't Call Me Shirley!" – The Seemingly Slapstick (But Yet Unfunny) World Of Recent Patent Term Extension Decisions (PART 3 . . . And PART 3½)

After waiting with bated breath for more than a week since posting spicy Part 1 and Part 2 of our three-part series on recent U.S. Patent and Trademark Office ("PTO") Patent Term Extension ("PTE")...
United StatesIntellectual Property
Hyman, Phelps, & McNamara
Hyman, Phelps, & McNamara
  • Article

    Long-Awaited Guidance On FDAMA 115: Confirmatory Evidence Finally Has Its Moment (To Be Crossed Off The FDA's Guidance To-Do List)

    This time last year, we wrote about a long-overlooked FDA statutory authority and wondered if this provision, known colloquially as the "single study plus confirmatory evidence" pathway...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
  • Article

    A Final LDT Rule In April!? Will FDA Be Prepared?

    With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
  • Article

    Can The Tropical PRV Have Its Moment (Again?) – Not All Priority Review Vouchers Are Created Alike: What The Potential Loss Of The Rare Pediatric PRV Could Mean For The Tropical Disease PRV Program

    Last December, Congress narrowly avoided a shutdown by significantly paring down the originally proposed 2025 Appropriations bill, slashing away hundreds of programs and laws.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Hyman, Phelps, & McNamara
    Hyman, Phelps, & McNamara
  • Article

    Agricultural Bioengineering: The Shifting Landscape

    The field of bioengineering is rapidly evolving with new tools that allow for simple, efficient, and highly-specific DNA and RNA editing.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Weekly Washington Healthcare Update - May 27, 2014

    This Week: Multiple House committees examine Medicare payment policies and reforms... Finance Committee advances Burwell HHS Secretary nomination.
    United StatesFood, Drugs, Healthcare, Life Sciences
    McGuireWoods LLP
    McGuireWoods LLP
  • Article

    Can What The Supreme Court Said About Device Clearance In Lohr, A "Derelict On The Waters Of The Law," Finally Be Sunk?<sup>1</sop>

    Even though they are still quoted, statements in Medtronic v. Lohr, which question whether FDA (Food & Drug Administration) medical device clearance is a judgment about a device's...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Butler Snow LLP
    Butler Snow LLP
  • Showing 241–249 of 249 results

    Previous
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics